marked.bio

SOS1 inhibitor · small molecule

BI 1701963

2 active trials across 2 of our biomarkers, targeting SOS1. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12C 2 5 Phase 1
KRAS G12D 2 4 Phase 1

Sponsors

Industry sponsors leading active biomarker-selected trials of BI 1701963.

  1. Boehringer Ingelheim 2

Trials

2 of 5 trials shown

  1. A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

    Active, not recruiting Phase 1 Boehringer Ingelheim Started 2021Primary completion 2026-11 NCT04973163

    BI 1823911BI 1701963midazolam

    KRAS mutation status: Kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation in tumour tissue or blood based on previously performed local testing using a v…

    KRAS G12CKRAS G12DSolid Tumors, KRAS Mutation

  2. A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

    Active, not recruiting Phase 1 Boehringer Ingelheim Started 2019Primary completion 2027-03 NCT04111458

    BI 1701963trametinib

    Previously-identified activating Kirsten rat sarcoma viral oncogene homologue (KRAS) mutation in tumour tissue or blood prior to screening

    KRAS G12CKRAS G12DSolid Tumors, KRAS Mutation; SOS1